Trump Administration
Refine Search
Pharmaceutical
US President Donald Trump issued an executive order on April 15 listing several potential policy changes aimed at lowering US drug prices.
Responding to the announcement, Morningstar’s healthcare equity research director Karen Andersen gave her views on why this matters. 18 April 2025
Pharmaceutical
US President Donald Trump has passed an executive order that answers the pharmaceutical industry’s calls for the scrapping of the Inflation Reduction Act’s (IRA) ‘pill penalty’. 16 April 2025
Pharmaceutical
New research from consultancy Vital Transformation has shown the effects of US policy the Inflation Reduction Act’s (IRA) drug pricing provisions on biopharmaceutical investment, research and development (R&D). 15 April 2025
Biotechnology
US sequencing firm PacBio is cutting jobs and reducing spending across its business as it braces for the financial impact of new global tariffs and growing uncertainty around federal research funding. 14 April 2025
Biotechnology
Shares in US biotech Novavax fell more than 20% before the weekend, following remarks from health and human services secretary Robert F Kennedy Jr, who questioned the scientific basis of the company’s COVID-19 vaccine in a televised interview. 14 April 2025
Pharmaceutical
Speculation about the US Administration’s views on the Pharmaceutical Benefits Scheme (PBS) has reconfirmed the sanctity of the PBS as the cornerstone of Australia’s healthcare system, the domestic pharma trade group stressed. 11 April 2025
Pharmaceutical
The US Centers for Medicare & Medicaid Services (CMS) has announced action intended to preserve the core mission of the Medicaid program against a wider backdrop of wider cost-cutting under the regime of President Donald Trump. 11 April 2025
Biotechnology
Licensing agreements for Chinese drug candidates hit a record high in 2024, with large pharma in-licensing 28% of innovator drugs from Chinese biopharma companies. 9 April 2025
Biotechnology
A federal commission has urged the US government to invest $15 billion to protect the country’s leadership in biotechnology and prevent China from outpacing American innovation in the field. The warning comes amid rising concern over growing reliance on foreign manufacturing and increasing Chinese activity in licensing biotech assets. 9 April 2025
Pharmaceutical
Ireland’s government remains confident in its ability to retain the country’s strategic position in pharmaceutical manufacturing, despite rising tensions between the European Union and the United States over trade policy. 8 April 2025
Pharmaceutical
Thousands of workers dismissed from the US Department of Health and Human Services this week may soon be reinstated, after health secretary Robert F Kennedy Jr admitted that a significant share of the job cuts were made in error. 7 April 2025
Pharmaceutical
In the news last week, US Center for Biologics Evaluation and Research (CBER) Dr Peter Marks quit his post after reported pressure from a Human Health Services (HHS) official. On the research front, Merck & Co presented positive Phase III data on its Winrevair in pulmonary arterial hypertension (PAH) at the American College of Cardiology (ACC) meeting. Also, Swiss biotech AC Immune shared new Phase II data on its Parkinson’s disease candidate ACI-7104-056. Late last Wednesday, US President Donald Trump dropped a bombshell of tariffs of various amounts on countries around the world, although there was ambiguity as to how and when they would impact pharma and biotech products. 6 April 2025
Biotechnology
US biotech Novavax is still waiting on a decision from the Food and Drug Administration over full approval of its protein-based COVID-19 vaccine, despite the agency having set an April 1 target date to complete its review. 4 April 2025
Pharmaceutical
Pharmaceuticals will be exempt from the tariffs on imports to the USA that were announced by US President Donald Trump Wednesday, according to a White House fact sheet. 3 April 2025
Pharmaceutical
Freed from their former obligations to remain loyal to agency and state, a number of high-profile figures from the US Food and Drug Administration (FDA) have sounded the alarm about its direction of travel under Robert Francis Kennedy Jr (RFK Jr), the new Secretary of Health and Human Services. 2 April 2025
Pharmaceutical
The US government is reclaiming over $11 billion in unspent public health funds originally allocated during the COVID-19 emergency, a move that has drawn sharp criticism from lawmakers and public health advocates who warn it will weaken the country’s ability to respond to future health threats and disrupt essential care services. 31 March 2025
Pharmaceutical
There has been talk of the job cuts impacting US health agencies for weeks. 27 March 2025
Pharmaceutical
The US Senate has confirmed President Donald Trump’s nominees to lead two of the country’s top health agencies, approving surgeon Marty Makary as Commissioner of the Food and Drug Administration and economist and physician Jay Bhattacharya as director of the National Institutes of Health. 27 March 2025
Biotechnology
The US Biotechnology Innovation Organization (BIO) has released results from a membership survey that underscores the significant, global integration of the biomedical supply chain. 27 March 2025
Pharmaceutical
The Trump administration plans to pull US funding from Gavi, the global vaccine alliance that helps deliver immunizations to children in lower-income countries, according to internal documents obtained by the New York Times. 26 March 2025
Pharmaceutical
The US Senate Finance Committee, led by Chairman Charles Grassley, has initiated its own investigation into drug pricing, with ranking member Ron Wyden calling on drugmakers to come before the group to account for recent price rises. 31 January 2019
Pharmaceutical
There has been plenty of angry discourse but little real action around US medicine prices in recent years, but the end of 2018 and the beginning of 2019 are offering evidence of change that is making drug companies sit up and take notice. 21 January 2019
Pharmaceutical
A new report from RBC Capital Markets investigates the potential impact of the ongoing US Government shutdown on the pharmaceutical industry. 16 January 2019
Pharmaceutical
A powerful committee of the freshly inaugurated Democrat-led US House of Representatives has launched a far-ranging investigation into the drug pricing practices of the US pharmaceutical industry. 15 January 2019
Biotechnology
US President Donald Trump's administration has been criticized for continuing to defend 'flawed' proposals for changing the way that Medicare drug prices are set. 11 January 2019
Pharmaceutical
The US House of Representatives has approved a bill that would prevent drugmakers from overcharging Medicaid in the way Mylan (Nasdaq: MYL) was famously accused of doing. 12 December 2018
Pharmaceutical
The US Food and Drug Administration has issued a statement detailing a new strategic framework to promote the use of real-world evidence (RWE) and real-world data (RWD) in the drug development process. 7 December 2018
Pharmaceutical
Drug-making is sometimes pictured as one of the last surviving “traditional” industries, successfully resisting waves of change that have overtaken other businesses. 5 December 2018
Pharmaceutical
A coalition of 55 Conservative groups and activists have voiced major concerns at President Donald Trump’s proposals on Medicare drug prices. 29 November 2018
Pharmaceutical
New rules proposed by the administration of US President Donald Trump would see insurers participating in the government-backed Medicare scheme permitted to exclude pharmaceuticals if price rises outpaced inflation. 27 November 2018
Pharmaceutical
Much like US politics as a whole, opinions are divided about what the midterm results mean for prescription drug prices. 8 November 2018
Pharmaceutical
Roche was one of the worst hit by pledges made by US President Donald Trump on Medicare drug prices on Thursday. 26 October 2018
Pharmaceutical
US Food and Drug Administration Commissioner Scott Gottlieb has welcomed the signing of new legislation that empowers agencies to take a range of actions to tackle the ongoing epidemic of opioid abuse in the country. 25 October 2018
Pharmaceutical
The White House has signalled its intention to press ahead with proposals to force drugmakers to include drug pricing information in direct-to-consumer advertising, despite the apparent inability of Congress to sign up to the idea. 16 October 2018
Pharmaceutical
US President Donald Trump has signed legislation preventing so-called ‘gag clauses,’ used for years by pharmacy benefit managers to restrict access to cheaper off-plan options. 11 October 2018
Pharmaceutical
The US Congress has agreed on a wide-ranging bill aimed at tackling the burgeoning epidemic of opioids abuse in the country, while rejecting a pharma industry amendment that would have reduced drugmakers' share of medicine costs under Medicare. 27 September 2018
Generics
A review of pending legislation from the non-partisan Congressional Budget Office (CBO) says the bill would allow generics to hit the shelves more quickly and enable the US Government to spend less on prescription drugs. 21 September 2018
Pharmaceutical
Lawmakers in the US House of Representatives have ditched a widely-supported amendment that would have changed the rules on advertising pharmaceutical products, requiring drugmakers to list prices in TV adverts. 19 September 2018
Biosimilars
The USA’s slow uptake of biosimilars compared to Europe and other markets has not helped to bring down the country’s notoriously high drug prices. 17 September 2018
Pharmaceutical
The USA spends about $3.3 trillion a year on health care, with about 10% of that spending for prescription drugs. Most Americans are very concerned about the high cost of prescription drugs. 14 September 2018
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze